Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

2.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.8K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

471
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
471
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.3K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.9K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

438
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
438
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

426
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
426

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Concomitant Intracardiac Shunt and Venous Collaterals After Fontan Procedure: A Case Report of Percutaneous Management.

Journal of cardiovascular development and disease·2026
Same author

Percutaneous repair following massive perforation of the right coronary artery with stent deployment toward the pericardium.

Coronary artery disease·2026
Same author

A Rare Presentation of Infective Endocarditis Complicating Severe Aortic Valve Stenosis.

Journal of cardiovascular development and disease·2026
Same author

Unexpected Findings in Diffuse ST-Segment Depression and aVR ST-Segment Elevation.

Diagnostics (Basel, Switzerland)·2026
Same author

Are Coronary Calcium-Modifying Techniques Levelling the Playfield?

Medicina (Kaunas, Lithuania)·2026
Same author

Conservative Management of Iatrogenic Type a Aortic Dissection Occurring During Percutaneous Coronary Intervention.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026

相关实验视频

Updated: Jan 18, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.2K

临床实践中弗莱卡尼德毒性的危险因素和标记物

Karim Khadir1, Georgiana Pintea Bentea1, Thomas Nguyen1

  • 1Department of Cardiology, CHU Brugmann, Brussels, Belgium.

CJC open
|January 16, 2026
PubMed
概括

弗莱卡因的毒性虽然令人担忧,但与代谢问题和特定的心律标志物有关,而不是传统的心脏病因素. 识别这些风险因素是更安全的患者管理的关键.

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.
  • 临床医学 临床医学

背景情况:

  • 弗莱卡尼德是心室和心室上心律不整的关键抗心律不整药.
  • 它的临床实用性受到潜在严重毒性的阻碍.
  • 了解当前的毒性模式,风险因素和标志物是必不可少的.

研究的目的:

  • 在当代临床实践中描述弗莱卡因的毒性.
  • 为了确定相关的风险因素和预测标志物,以确定飞胺的毒性.

主要方法:

  • 对300名接受弗莱卡尼德 (2014-2022) 的患者进行了回顾性单中心分析.
  • 最低3个月的随访期.
  • 具有和没有弗莱卡因毒性患者之间的基线特征的比较.

主要成果:

  • 13%的患者 (39/300) 发生了弗莱卡尼德毒性,死亡率为18%.
  • 危险因素包括鼻肌梗塞,慢性病,肝硬化,药物相互作用,以及治疗期间特定的心电图/心电图发现.
  • 基线缺血性或结构性心脏病并不是一个显著的风险因素.

结论:

关键词:
弗莱卡尼尼德是一种类物质.弗莱卡尼德的毒性有关风险因素的风险因素.

更多相关视频

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.5K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.9K

相关实验视频

Last Updated: Jan 18, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.2K
Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.5K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.9K
  • 弗莱卡尼德的毒性对患者的发病率和死亡率有很大影响.
  • 代谢因素 (心脏病,肝硬化,药物相互作用) 和临床前标志物 (胸心,LVEF,QT/QRS间隔) 是关键预测因素.
  • 传统的禁忌,如 LV 功能障碍,并不是 flecainide 毒性的主要危险因素.